Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2018

View Archived Issues

Study points to new bone building strategy

Oncobiologics begins first clinical trial for ONS-5010 in wet AMD

Codexis announces topline results from phase Ia study of CDX-6114

Myonexus Therapeutics initiates study of first-ever gene therapy for beta-sarcoglycanopathy

Cell-combination delivery of anti-PD-1 antibody induces potent antileukemia responses in mice

Aquinnah Pharmaceuticals divulges new TDP-43 aggregation inhibitors

Neurocrine Biosciences presents SLC18A2 inhibitors

In situ delivery and retention of cytotoxic drugs with AvidinOX improve their antitumor efficacy

Neurotensin (8-13) analogue demonstrates anxiolytic potential in chronic pain models

Takeda Pharmaceutical presents first preclinical results for LSD1 inhibitor T-448

Activated mesenchymal stem cells show robust preclinical results for treating ischemic stroke

Neurotensin type 1 receptor pepducin PP-001 shows analgesic activity in vivo

Tempest Therapeutics discloses prostanoid EP4 receptor antagonists

Gene therapy based on newly discovered EBP50 mutation improves neuropathy

EA Pharma signs joint research agreement to advance E-6011 for Crohn's disease

Palatin reports first-in-human data on subcutaneous dosing with MC1 receptor agonist peptide PL-8177

Innovent presents data on sintilimab in first-line squamous NSCLC

Cue Biopharma and LG Chem collaborate to develop Immuno-STAT biologics for cancer

European Commission approves expanded label for Trelegy Ellipta in COPD

Chemokine receptor 8 identified as a marker of ANCA-negative ANCA-associated vasculitis

Inhibiting N-glycase-1 increases the efficacy of chemotherapy in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...